Objective To evaluate the effects of carvedilol on the cardiac function and serum leptin lever in the treatment of diabetic cardiomyopathy.Methods 40 patients with diabetic cardiomyopathy were randomly divided into carvedilol group and control group.Two groups were given normal therapy and the carvedilol group added carvedilol.The serum levels of leptin and insulin and the heart ultrasound check were measured before and after six months of therapy.Results After therapy the serum levels of leptin and insulin resistance index [ ( 7.18 ± 2.06 ) μg/L,(2.92 ± 0.62) ] were blower than that before therapy in carvedilol group but not control group.After therapy the value of LVEF and E/A were higher[ (46.9 ± 6.8) ％,( 1.05 ± 0.07) ] and LVMI and LVEDd were lower[ ( 108 ± 6 ) g/ m2,(51.8 ± 5.7)mm ] than that before therapy in carvedilol group but not control group( all P ＜ 0.05 ).Conclusion Carvedilol could decrease the levels of serum leptin in patient with diabetic cardiomyopathy and improve insulin resistance and left entricular function.

Antihypertensive Agents ; therapeutic use ; Humans ; Vaccines

Objective To investigate the influence of newborns born to mother with systemic lupus erythematosus (SLE).Method The clinical data of SLE mothers and their infants bern in the obstetric and were admitted to the neonatal ward ward of the First Affiliated Hospital of Guangxi Medical University from July 2012 to March 2015 were studied retrospectively.The infants were divided into active SLEactivity group and stable SLE group.The incidence of preterm birth,small for gestational age (SGA),cardiac conduction block,anemia,and thrombocytopenia were compared between the two groups of SLE mothers.Result A total of 66 infants were included in SLE mothers,including 14 cases (21.2％) of preterm infants and 18 cases of SGA (27.3％).14 cases belonged to the active SLE group while 52 cases belonged to the SLE stable group.When comparing the 2 groups,there were no differences found on the rates of preterm infant and small for gestational age (P ＞ 0.05).The cardiac conduction block,anemia and thrombocytopenia happened separately in three cases of the active group,which had not seen in the SLE stable group.There was no statistically significant difference between the two groups (P ＞ 0.05).Of the 66 cases,2 were diagnosed with neonatal lupus erythematosus (NLE) with an incidence of 3％.Conclusion SLE mothers with an active disease 10 days before delivery did not significantly increase the incidence of preterm infants and SGA,but were at risk of NLE.

BACKGROUND: Pathogenesy of immunoglobulin A nephropathy (IgAN) is not clear up to now. Present research has verified that the key pathogenetic pathway is abnormalities of IgA1 molecular O-glycosylation induced by decrease of ?1,3-galactosyltranferase activity in IgA1 hinge region of IgAN patients. Prophase study by the authors supposed that the key of IgAN O-glycosylation abnormality might be due to the decrease of ?1,3-galactosyltranferase specific molecular protein chaperone Cosmc in B lymphocyte of peripheral blood in IgAN patients. OBJECTIVE: To measure DNA sequence of ?1,3-galactosyltranferase specific molecular chaperone in coding region of Cosmc gene in IgAN patients,and compared with the sequence of Gene Bank. DESIGN: Case-controlled observation. SETTING: Department of Nephrology,West China Hospital,Sichuan University. PARTICIPANTS: Totally 27 IgAN patients and 10 non-IgAN patients were recruited in Department of Nephrology of West China Hospital of Sichuan University from November 2005 to August 2006,and five normal controls were included in this study. All the subjects knew the fact and agreed to participate in the experiment. METHODS: The experiment was performed at the State Key Laboratory of Biotherapy of Sichuan University. 2 mL peripheral venous blood of all the samples were taken into heparin sodium anticoagulated tubes,from which total genomic DNA were extracted by phenol/chloroform precipitation method. Concentration of DNA was determined by ultraviolet spectrophotometer. The polymerase chain reaction (PCR) was used to amplify the coding region of ?1,3-galactosyltranferase specific molecular chaperone Cosmc gene in all the subjects and direct sequencing was done in PCR products of each subjects. The results of all the sequencing were compared with Gene Bank one by one. MAIN OUTCOME MEASURES: Amplification findings and sequencing of coding region of ?1,3-galactosyltranferase specific molecular chaperone Cosmc gene by PCR. RESULTS: ①Coding region of Cosmc gene located at 257-1 213,and amplified Cosmc gene was 1 247 bp. ②The sequence of Cosmc gene coding region was similar in IgAN patients,non-IgAN patients and normal controls,and no difference of gene sequence was noticed in all the result sequences as compared with the Gene Bank registered sequence. CONCLUSION: No abnormal sequence is found in coding region of Cosmc gene in IgAN patients,suggesting that this coding region probably is not associated with the abnormalities of IgA1 O-glycosylation in IgAN.

Objective To explore the relation between serum nesfatin-1 ,tumor necrosis factor (TNF)-αand insulin resistance. Methods A total of 105 subjects were enrolled in this study and divided into two groups:patients with newly diagnosed type 2 diabetes mellitus (T2DM group,n= 64)and normal controls (NC group,n= 41). The fasting serum nesfatin-1 and TNF-αlevels were measured by enzyme-linked immuno sorbent assay (ELISA). FPG,HbA1 c,TG,TC,and FIns were also tested. BMI, HOMA-IR,HOMA-β,and ISI were calculated. Results Serum nesfatin-1 and TNF-αlevels were significantly higher in T2DM group than in NC group. Multiple linear regression analysis showed that the most significant influencing factors for nesfatin-1 were TNF-αand ISI(β= 0. 005、-6. 847,P<0. 05). The most significant influencing factors for TNF-αwas HbA1 c (β= 26. 652,P<0. 01). Conclusion Serum nesfatin-1 and TNF-αare significantly elevated in patients with newly diagnosed T2DM,which may influence the glucolipid metabolism through the signal pathway of insulin and play a role in the pathogenesis of T2DM and IR.

10.3969/j.issn.2095-4344.2013.24.019

Angiotensin-Converting Enzyme Inhibitors ; therapeutic use ; Follow-Up Studies ; Heart Failure ; drug therapy ; Humans ; Retrospective Studies

Cardiovascular Diseases ; drug therapy ; Humans ; Renin ; antagonists & inhibitors

Adult ; Humans ; Lead Poisoning, Nervous System ; etiology ; Male

Cardiovascular Agents ; therapeutic use ; Chronic Disease ; Clinical Trials as Topic ; Coronary Disease ; drug therapy ; Double-Blind Method ; Humans